Barclays Has Lowered Expectations for Aspen Aerogels (NYSE:ASPN) Stock Price

Aspen Aerogels (NYSE:ASPN) had its target price reduced by Barclays from $27.00 to $25.00 in a research note issued to investors on Tuesday,Benzinga reports. Barclays currently has an overweight rating on the construction company’s stock.

Other equities analysts have also recently issued research reports about the company. TD Cowen upped their price target on Aspen Aerogels from $36.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, August 20th. StockNews.com raised shares of Aspen Aerogels to a “sell” rating in a research report on Thursday, October 31st. Roth Mkm reduced their price objective on shares of Aspen Aerogels from $36.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Benchmark reissued a “buy” rating and set a $14.00 price target on shares of Aspen Aerogels in a research report on Thursday, August 8th. Finally, Piper Sandler lowered their target price on shares of Aspen Aerogels from $36.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $28.70.

Aspen Aerogels Price Performance

ASPN opened at $15.80 on Tuesday. The company has a 50 day moving average of $22.87 and a two-hundred day moving average of $24.74. Aspen Aerogels has a 52-week low of $8.79 and a 52-week high of $33.15. The company has a quick ratio of 2.82, a current ratio of 3.46 and a debt-to-equity ratio of 0.23. The company has a market cap of $1.22 billion, a P/E ratio of 1,581.58 and a beta of 2.21.

Insider Buying and Selling

In other news, CEO Donald R. Young sold 63,355 shares of the stock in a transaction on Monday, September 30th. The stock was sold at an average price of $30.03, for a total value of $1,902,550.65. Following the completion of the transaction, the chief executive officer now owns 483,640 shares of the company’s stock, valued at approximately $14,523,709.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CFO Ricardo C. Rodriguez sold 32,465 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $30.14, for a total transaction of $978,495.10. Following the completion of the transaction, the chief financial officer now owns 20,790 shares in the company, valued at approximately $626,610.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Donald R. Young sold 63,355 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the sale, the chief executive officer now directly owns 483,640 shares of the company’s stock, valued at approximately $14,523,709.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Aspen Aerogels

Institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets lifted its holdings in shares of Aspen Aerogels by 85.2% in the first quarter. BNP Paribas Financial Markets now owns 25,706 shares of the construction company’s stock valued at $452,000 after purchasing an additional 11,823 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in shares of Aspen Aerogels in the 1st quarter valued at approximately $388,000. Swiss National Bank lifted its stake in Aspen Aerogels by 16.2% in the first quarter. Swiss National Bank now owns 120,500 shares of the construction company’s stock valued at $2,121,000 after acquiring an additional 16,800 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Aspen Aerogels by 5.1% during the 1st quarter. Vanguard Group Inc. now owns 3,619,702 shares of the construction company’s stock worth $63,707,000 after purchasing an additional 175,906 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in Aspen Aerogels during the first quarter valued at about $851,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.